To date, this agent has been tested in three randomized Phase 2 trials of metastatic cancer: in combination with paclitaxel versus paclitaxel alone in platinum-resistant/refractory ovarian cancer (NCT01447706); in combination with exemestane versus exemestane plus placebo in ER/PR+ HER2− breast cancer (NCT01151046); and in combination with erlotinib versus erlotinib alone in EGFR wild-type NSCLC (NCT00994123). Here, ERBB2 is linked to ovarian carcinoma.